BioLineRx Reports 2025 Financial Results and Provides Corporate Update

BioLineRx Reports 2025 Financial Results and Provides Corporate Update Accessibility StatementSkip Navigation - On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end of this month - - GLIX1 is positioned to potentially address unmet needs for novel and more effective cancer treatments by targeting DNA damage response mechanisms - Clinical UpdatesGLIX1 On track to initiate a Phase 1/2a clinical trial of GLIX1 in glioblastoma by the end of the month. - Management t ...